BAGEL, J.; ARMSTRONG, A. W.; WARREN, R. B.; PAPP, K. A.; THAÇI, D.; MENTER, A.; CATHER, J.; AUGUSTIN, M.; HIPPELI, L.; DAAMEN, C.; GRIFFITHS, C. E. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s117, 2023. DOI: 10.25251/skin.7.supp.117. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1969. Acesso em: 4 jul. 2024.